Drug Profile

Research programme: KCNQ potassium channel openers - Xenon Pharmaceuticals

Alternative Names: KCNQ potassium channel openers - Xenon Pharmaceuticals; Kv7 potassium channel openers - Xenon Pharmaceuticals

Latest Information Update: 18 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Xenon Pharmaceuticals
Class Analgesics; Antiepileptic drugs; Behavioural disorder therapies; Small molecules
Mechanism of Action KCNQ potassium channel agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 Nov 2024 Xenon Pharmaceuticals announces intention to submit IND to regulatory body in December 2025
03 Jul 2024 Preclinical trials in Epilepsy in Canada (unspecified route), before July 2024 (Xenon Pharmaceuticals pipeline, July 2024)
03 Jul 2024 Preclinical trials in Pain in Canada (unspecified route), before July 2024 (Xenon Pharmaceuticals pipeline, July 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com